Vanguard Group Inc. decreased its position in Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) by 1.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,680,444 shares of the biotechnology company's stock after selling 59,727 shares during the period. Vanguard Group Inc. owned 5.52% of Anavex Life Sciences worth $50,268,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of AVXL. PVG Asset Management Corp acquired a new stake in shares of Anavex Life Sciences during the third quarter valued at about $74,000. BNP Paribas Financial Markets increased its holdings in Anavex Life Sciences by 97.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company's stock valued at $86,000 after purchasing an additional 7,421 shares during the last quarter. Berkshire Money Management Inc. purchased a new stake in Anavex Life Sciences in the fourth quarter valued at approximately $107,000. Fiduciary Alliance LLC acquired a new position in Anavex Life Sciences during the fourth quarter worth $119,000. Finally, D.A. Davidson & CO. purchased a new position in shares of Anavex Life Sciences during the fourth quarter worth $122,000. 31.55% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several equities analysts have weighed in on the company. D. Boral Capital reaffirmed a "buy" rating and issued a $46.00 target price on shares of Anavex Life Sciences in a research report on Monday, April 7th. HC Wainwright reissued a "buy" rating and set a $42.00 price objective on shares of Anavex Life Sciences in a research report on Monday, April 7th.
Get Our Latest Stock Analysis on AVXL
Anavex Life Sciences Price Performance
Shares of AVXL traded down $0.09 during mid-day trading on Thursday, reaching $8.75. The company's stock had a trading volume of 74,101 shares, compared to its average volume of 1,252,948. Anavex Life Sciences Corp. has a 12-month low of $3.25 and a 12-month high of $14.44. The company's 50 day moving average is $8.71 and its 200 day moving average is $8.57. The stock has a market cap of $744.65 million, a PE ratio of -15.86 and a beta of 0.80.
Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.03. As a group, sell-side analysts anticipate that Anavex Life Sciences Corp. will post -0.69 EPS for the current fiscal year.
About Anavex Life Sciences
(
Free Report)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
Read More
Before you consider Anavex Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.
While Anavex Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
